Recce Pharmaceuticals deepens US partnership to advance burn wound treatment

Recce Pharmaceuticals (ASX:RCE) is expanding its collaboration with the U.S. Military through a second Cooperative Research and Development Agreement (CRADA). This new agreement signifies a strengthened relationship with a key U.S. Government research institution.

Advancing Burn Wound Treatment

The latest CRADA, established with the U.S. Army Institute of Surgical Research (USAISR), will concentrate on the development of RECCE 327 Gel as a treatment for burn wound infections. The USAISR is recognized as the U.S. Army’s primary resource for research into combat casualty care and burn treatment.

Testing Methodology

The USAISR will utilize its Walker-Mason rat model to evaluate RECCE 327 Gel. This preclinical system is designed to simulate battlefield burn injuries and the resulting systemic infections. The study will specifically assess the gel’s ability to reduce bacterial burden in infected burn wounds, focusing on Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.

Did You Know? Burn wound infections are a leading cause of death for patients with severe burns, in both military and civilian settings.

The increasing challenge of antimicrobial resistance is undermining the effectiveness of traditional antibiotics. Recce’s synthetic anti-infective platform is attracting attention for its potential to provide rapid, broad-spectrum antimicrobial action without contributing to the development of resistance.

RECCE 327 Gel: A Practical Solution

RECCE 327 Gel is formulated as a hydrogel wound dressing intended for practical use in the field. Its design aims for suitability in military field kits, hospital burn units and post-operative wound care. The company states the gel’s ability to maintain effectiveness with repeated use and its low potential to induce bacterial resistance set it apart from current therapies.

Expert Insight: The focus on developing a treatment that can be reliably used in frontline settings highlights the critical need for solutions that address the unique challenges of combat-related injuries, and infections.

This agreement with USAISR complements Recce’s existing CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Combined with a recent U.S. Government grant, this partnership demonstrates growing confidence in Recce’s technology across various applications.

James Graham, Chief Executive Officer of Recce Pharmaceuticals, stated the company is proud to strengthen its relationship with the U.S. Army. He believes the hydrogel delivery system for RECCE 327 offers a practical solution for combat wound care, with potential benefits for both military and civilian healthcare.

Frequently Asked Questions

What is the purpose of the new CRADA?

The new CRADA with the U.S. Army Institute of Surgical Research (USAISR) will focus on advancing Recce’s RECCE 327 Gel for the management of burn wound infections.

What makes RECCE 327 Gel different from existing treatments?

According to the company, RECCE 327 Gel’s ability to maintain efficacy with repeated use and its low risk of inducing bacterial resistance distinguish it from existing therapies.

Has Recce Pharmaceuticals collaborated with the U.S. Military before?

Yes, Recce Pharmaceuticals has an existing CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

As research progresses, will this technology have the potential to impact treatment options for burn victims beyond the military context?